| Literature DB >> 33862588 |
Guanglin Cui1, Qingbo Fan2, Zhenfeng Li3, Rasmus Goll4, Jon Florholmen4.
Abstract
Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal biomarker analysis revealed that faecal calprotectin, C-reactive protein, serum or mucosal concentrations of anti-TNF monoclonal antibodies (mAbs) and antibodies to anti-TNF mAbs are commonly used as current biomarkers in the evaluation of anti-TNF therapeutic efficacy. However, mucosal cytokine transcripts. microRNAs, proteomics and faecal and mucosal gut microbiota profile and mucosal histological features are reported to be novel candidates of biomarkers with high clinical utility in the evaluation of anti-TNF therapeutic efficacy in patients with IBD. Therefore, a robust validation of novel promising biomarkers and comparison studies between current used and novel biomarkers are urgently required to improve their value in the evaluation of therapeutic efficacy and optimization of personalized medicine and identification of IBD candidates for anti-TNF therapy in future clinical practice.Entities:
Keywords: Anti-TNF therapy; Biomarker; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis
Year: 2021 PMID： 33862588 DOI： 10.1016/j.ebiom.2021.103329
Source DB: PubMed Journal: EBioMedicine ISSN： 2352-3964 Impact factor: 8.143